Osseon Receives Second Patent Allowance for Minimally Invasive Vertebral Compression Fracture Treatment Devices
SANTA ROSA, Calif., Oct. 4 /PRNewswire/ -- Osseon Therapeutics, Inc., a biomedical device company based in Santa Rosa, California, received its second patent Notice of Allowance (NOA) for its spinal vertebral compression fracture (VCF) technology. The company, which was started in 2006, now has two allowed and twelve additional patent applications pending in the United States, and several others throughout the world for spinal therapies and devices.
The company has been marketing its FDA and CE Mark cleared "Osseoplasty™" system in the U.S. and Europe, since February, 2009 and February, 2010, respectively. The proprietary Osseoplasty™ procedure has been performed in over 1,100 patients in the U.S. and Europe.
According to John Stalcup, Ph.D., President and CEO of Osseon, "This second patent allowance for Osseon's spinal VCF technology is another cornerstone for the company's intellectual property foundation. We continue to strengthen our intellectual property position and strive to obtain additional patents in the future on various aspects of the Osseoflex® steerable and curvable needle and the novel methods for bone cement delivery, which enable a safe, effective, and minimally invasive approach for spine disease treatment."
ABOUT Osseon Therapeutics, Inc.
About Osseon
Osseon Therapeutics, Inc. focuses on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease. Headquartered in Santa Rosa, CA, the company's groundbreaking technology and delivery system provides comparable or better efficacy and safety than other commercial solutions while offering significant advantages in efficiency and cost. By improving the treatment of compression fractures within the thoracic and lumbar vertebral spine, Osseon offers alternative solutions to patients suffering from these maladies, as well as the physicians and medical facilities that treat them. Its first-generation products have received both FDA clearance and the CE Mark for product distribution in the United States and European Union. For more information, visit our web site at www.osseon.com.
Osseon® and Osseoflex® are registered trademarks, and Osseoplasty™ is a trademark of Osseon Therapeutics, Inc. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.
SOURCE Osseon Therapeutics, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article